Novel sulphonamide-bearing methoxyquinazolinone derivatives as anticancer and apoptosis inducers: synthesis, biological evaluation and in silico studies

References

• Clark W. Tumour progression and the nature of cancer. Br J Cancer 1991;64:631–44.
   PubMed Web of Science ®Google Scholar
• DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res 2008;68:8643–53.
   PubMed Web of Science ®Google Scholar
• Arruebo M, Vilaboa N, Sáez-Gutierrez B, et al. Assessment of the evolution of cancer treatment therapies. Cancers (Basel) 2011;3:3279–330.
   PubMedGoogle Scholar
• Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol 2019;54:407–19.
   PubMed Web of Science ®Google Scholar
• Peitzsch C, Perrin R, Hill RP, et al. Hypoxia as a biomarker for radioresistant cancer stem cells. Int J Radiat Biol 2014;90:636–52.
   PubMed Web of Science ®Google Scholar
• Sugrue T, Lowndes NF, Ceredig R. Hypoxia enhances the radioresistance of mouse mesenchymal stromal cells. Stem Cells 2014;32:2188–200.
   PubMed Web of Science ®Google Scholar
• Daniel KG, Gupta P, Harbach RH, et al. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 2004;67:1139–51.
   PubMed Web of Science ®Google Scholar
• Luqmani Y. Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract 2005;14(Suppl 1):35–48.
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007;6:667–74.
   PubMed Web of Science ®Google Scholar
• Ling YH, Lin R, Perez-Soler R. Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol 2008;74:793–806.
   PubMed Web of Science ®Google Scholar
• Chao T-T, Wang C-Y, Chen Y-L, et al. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget 2015;6:2164–79.
   PubMedGoogle Scholar
• Zhao Z-Q, Yu Z-Y, Li J, Ouyang X-N. Gefitinib induces lung cancer cell autophagy and apoptosis via blockade of the PI3K/AKT/mTOR pathway. Oncol Lett 2016;12:63–8.
   PubMed Web of Science ®Google Scholar
• George JA, Alshebli Z, Alneyadi A, et al. Idelalisib induces apoptosis in the lymphoid tissues and impairs lung function in mice. J Chemother 2020;32:88–97.
   PubMed Web of Science ®Google Scholar
• Ghorab MM, Alsaid MS, Soliman AM, Al-Mishari AA. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors. J Enzyme Inhib Med Chem 2018;33:67–73.
   PubMed Web of Science ®Google Scholar
• Traxler P. Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin Ther Targets 2003;7:215–34.
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002;62:5749–54.
   PubMed Web of Science ®Google Scholar
• Gong HH, Addla D, Lv JS, Zhou CH. Heterocyclic naphthalimides as new skeleton structure of compounds with increasingly expanding relational medicinal applications. Curr Top Med Chem 2016;16:3303–64.
   PubMed Web of Science ®Google Scholar
• Kashyap M, Das D, Preet R, et al. Scaffold hybridization in generation of indenoindolones as anticancer agents that induce apoptosis with cell cycle arrest at G2/M phase. Bioorg Med Chem Lett 2012;22:2474–9.
   PubMed Web of Science ®Google Scholar
• Lubenets V, Lviv Polytechnic National University, Karpenko O, Ponomarenko M, Zahoriy G, Krychkovska A, Novikov V. Development of new antimicrobial compositions of thiosulfonate structure. Chem Chem Technol 2013;7:119–24.
   Google Scholar
• Lubenets V, Vasylyuk S, Monka N, et al. Synthesis and antimicrobial properties of 4-acylaminobenzenethiosulfoacid S-esters. Saudi Pharm J 2017;25:266–74.
   PubMed Web of Science ®Google Scholar
• Harmey JH, Bouchier‐Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: Implications for anti-angiogenic therapy. Bioessays 2002;24:280–3.
   PubMed Web of Science ®Google Scholar
• Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374–8.
   PubMed Web of Science ®Google Scholar
• Ghorab MM, El Ella DAA, Heiba HI, Soliman AM. Synthesis of certain new thiazole derivatives bearing a sulfonamide moiety with expected anticancer and radiosensitizing activities. J Mater Sci 2011;3:31.
   Google Scholar
• Mills CC, Kolb EA, Sampson VB. Development of chemotherapy with cell-cycle inhibitors for adult and pediatric cancer therapy. Cancer Res 2018;78:320–5.
   PubMed Web of Science ®Google Scholar
• Bai J, Li Y, Zhang G. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med 2017;14:348–62.
   PubMed Web of Science ®Google Scholar
• Heishima K, Mori T, Sakai H, et al. MicroRNA-214 promotes apoptosis in canine hemangiosarcoma by targeting the COP1-p53 axis. PLoS One 2015;10:e0137361.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
   PubMed Web of Science ®Google Scholar
• Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876–85.
   PubMed Web of Science ®Google Scholar
• Plesca D, Mazumder S, Almasan A. DNA damage response and apoptosis. Methods Enzymol 2008;446:107–22.
   PubMed Web of Science ®Google Scholar
• Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ 2018;25:65–80.
   PubMed Web of Science ®Google Scholar
• Perlman H, Zhang X, Chen MW, et al. An elevated bax/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ 1999;6:48–54.
   PubMed Web of Science ®Google Scholar
• Al-Shabib NA, Khan JM, Malik A, et al. Molecular insight into binding behavior of polyphenol (rutin) with beta lactoglobulin: spectroscopic, molecular docking and MD simulation studies. J Mol Liquids 2018;269:511–20.
   Web of Science ®Google Scholar
• Campbell KJ, Tait SWG. Targeting BCL-2 regulated apoptosis in cancer. Open Biol 2018;8:180002.
   PubMed Web of Science ®Google Scholar
• Salam AAA, Nayek U, Sunil D. Homology modeling and docking studies of Bcl-2 and Bcl-xL with small molecule inhibitors: identification and functional studies. Curr Top Med Chem 2018;18:2633–63.
   PubMed Web of Science ®Google Scholar
• Alqahtani AS, Nasr FA, Noman OM, et al. Cytotoxic evaluation and anti-angiogenic effects of two furano-sesquiterpenoids from Commiphora myrrh resin. Molecules 2020;25:1318.
   PubMed Web of Science ®Google Scholar
• Porter J, Payne A, de Candole B, et al. Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors. Bioorg Med Chem Lett 2009;19:230–3.
   PubMed Web of Science ®Google Scholar
• Rehman MT, Shamsi H, Khan AU. Insight into the binding mechanism of imipenem to human serum albumin by spectroscopic and computational approaches. Mol Pharm 2014;11:1785–97.
   PubMed Web of Science ®Google Scholar
• Rabbani N, Tabrez S, Islam BU, et al. Characterization of colchicine binding with normal and glycated albumin: In vitro and molecular docking analysis. J Biomol Struct Dyn 2018;36:3453–62.
   PubMed Web of Science ®Google Scholar
• Rehman MT, Ahmed S, Khan AU. Interaction of meropenem with 'N' and 'B' isoforms of human serum albumin: a spectroscopic and molecular docking study. J Biomol Struct Dyn 2016;34:1849–64.
   PubMed Web of Science ®Google Scholar